RxDoctor Payments Data

Freida Lambert

Family · Mullens, WVNPI 1962854216

Payments from drug & device makers

$1,475in general payments, 2019–2025

Across 85 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$328
  • Novo Nordisk$231
  • AbbVie$223
  • GSK$213
  • Lilly USA, LLC$134
  • Idorsia Pharmaceuticals US Inc$122
  • plus $225 from 8 others

What the payments were for

  • Food & beverage$1,475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,475 in reported general payments places this provider in the 70th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$27,732
Medicare patients
74
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$69,563
EliquisApixaban30$49,111
LinzessLinaclotide37$39,097
MounjaroTirzepatide29$36,789
EntrestoSacubitril/Valsartan23$34,941
JanuviaSitagliptin Phosphate21$29,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$25,661
VascepaIcosapent Ethyl23$21,644
FarxigaDapagliflozin Propanediol14$19,616
JardianceEmpagliflozin12$18,819
TradjentaLinagliptin21$18,804
XifaxanRifaximin11$16,895
Breo ElliptaFluticasone/Vilanterol20$12,021
BrilintaTicagrelor15$10,175
Buprenorphine19$8,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$231$69,56339 claims
PfizerEliquis, Paxlovid$21$50,50242 claims
AbbVieLinzess, Synthroid$223$40,66352 claims
GSKTrelegy Ellipta, Breo Ellipta$213$37,68336 claims
Boehringer IngelheimJardiance, Tradjenta$39$37,62433 claims
Lilly USA, LLCMounjaro$134$36,78929 claims
NovartisEntresto$22$34,94123 claims
AstraZenecaFarxiga, Brilinta$328$29,79129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,507 family providers in West Virginia.

Other family in Mullens

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →